In the absence of MET amplification, MET has been found to be overexpressed in a variety of cancers, such as RCC [19], NSCLC [112], malignant pleural mesothelioma (MPM) [113], glioblastoma multiforme (GBM) [114], and gastric cancer (GC) [115]. Here, MET is linked to glioblastoma.